Fortrea Holdings (K67) Stock Overview
A contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
K67 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Fortrea Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.10 |
| 52 Week High | US$15.40 |
| 52 Week Low | US$3.92 |
| Beta | 2.01 |
| 1 Month Change | 16.15% |
| 3 Month Change | 76.61% |
| 1 Year Change | 262.98% |
| 3 Year Change | -48.64% |
| 5 Year Change | n/a |
| Change since IPO | -48.64% |
Recent News & Updates
Recent updates
Shareholder Returns
| K67 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 0.7% | -0.5% | -0.4% |
| 1Y | 263.0% | 1.7% | -0.8% |
Return vs Industry: K67 exceeded the German Life Sciences industry which returned 1.7% over the past year.
Return vs Market: K67 exceeded the German Market which returned -0.8% over the past year.
Price Volatility
| K67 volatility | |
|---|---|
| K67 Average Weekly Movement | 13.3% |
| Life Sciences Industry Average Movement | 6.0% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: K67's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: K67's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2023 | 14,000 | Anshul Thakral | www.fortrea.com |
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services.
Fortrea Holdings Inc. Fundamentals Summary
| K67 fundamental statistics | |
|---|---|
| Market cap | €1.47b |
| Earnings (TTM) | -€390.68m |
| Revenue (TTM) | €2.37b |
Is K67 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| K67 income statement (TTM) | |
|---|---|
| Revenue | US$2.71b |
| Cost of Revenue | US$2.20b |
| Gross Profit | US$510.90m |
| Other Expenses | US$957.80m |
| Earnings | -US$446.90m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Jul 29, 2026
| Earnings per share (EPS) | -4.72 |
| Gross Margin | 18.86% |
| Net Profit Margin | -16.50% |
| Debt/Equity Ratio | 200.4% |
How did K67 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/19 10:17 |
| End of Day Share Price | 2026/07/17 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Fortrea Holdings Inc. is covered by 13 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eric Coldwell | Baird |
| Luke Sergott | Barclays |
| Michael Ryskin | BofA Global Research |